TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03704545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical consultation at the hospital
Description: During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical consultation at the pharmacy
Description: During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up pharmaceutical consultation at the pharmacy
Description: During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
Study: NCT04600648

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum insulin level
Description: Measure levels before and after weight loss related to bariatric surgery

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Leptin test
Description: Measure levels before and after weight loss related to lifestyle change weight loss
Study: NCT01478698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA 10mg per dose intraperitoneal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA 10mg per dose intraperitoneal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA 10mg per dose intraperitoneal
Study: NCT03530007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: normal saline used for prevention of spinal shivering
Study: NCT01478698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant deoxyribonuclease (DNase)
Description: DNase 5mg per dose given intraperitoneally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant deoxyribonuclease (DNase)
Description: DNase 5mg per dose given intraperitoneally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant deoxyribonuclease (DNase)
Description: DNase 5mg per dose given intraperitoneally.
Study: NCT00466193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate sublingual tablet
Description: 3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Study: NCT03530007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: ondansetron 4 MG used for prevention of spinal shivering
Study: NCT02304042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin will be given slowly iv after delivery of the anterior shoulder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be given slowly iv after delivery of the anterior shoulder.
Study: NCT01375049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam for Inhalation Solution (AZLI)
Description: AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
Study: NCT04065724

Intervention type: OTHER
Group type: OTHER
Intervention: Physical training as resistance and aerobic training.
Study: NCT03394391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily ART-adherence SMS reminder
Description: Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Adherence Counselling/Patient experience group chat
Description: All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Adherence Counselling/Patient experience group chat
Description: All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges.
Study: NCT03837691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of Snowshoe Suture Anchors
Description: Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Diet & Exercise Program
Description: After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
Study: NCT03530007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: ondansetron 8 MG used for prevention of spinal shivering
Study: NCT02563158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-occlusion technique
Description: Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
Study: NCT01383902

Intervention type: OTHER
Group type: OTHER
Intervention: Food type
Description: 1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
Study: NCT01363778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
Study: NCT01484470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StemEx
Description: For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up.
Study: NCT04619316

Intervention type: DRUG
Group type: OTHER
Intervention: Trametinib 2 MG [Mekinist]
Description: Monotherapy with Trametinib is given in patients with BRAF wildtype.

Intervention type: DRUG
Group type: OTHER
Intervention: Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]
Description: Combination therapy is given in patients with BRAF V600E mutation.
Study: NCT03056703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: One Fast Release Tablet containing 1000 mg acetylsalicylic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
Study: NCT03004534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darolutamide
Description: Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
Study: NCT03311074

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Strimvelis
Description: Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
Study: NCT01086553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 9mg budesonide OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: 3mg budesonide TID
Study: NCT02036905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical and thoracic mobilization
Description: Described in arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical and thoracic manipulation
Description: described in arm description
Study: NCT02477020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 20 mg
Description: TAK-063 tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-063 matching-placebo tablet.
Study: NCT01766375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A,mycophenolate mofetil,Methotrexate
Description: GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A,mycophenolate mofetil,Methotrexate
Description: GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
Study: NCT00075868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03431194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midodrine
Description: oral midodrine tablets 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02442921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: up to 2mg of Colchicine daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo
Study: NCT01379326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
Study: NCT04660123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
Description: Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d.
Study: NCT01040429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients \> 35 kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose capsula
Description: Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg
Study: NCT03689127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated breathing circuit on
Description: Heated breathing circuit will be turned on.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated breathing circuit off
Description: Heated breathing circuit will be turned off.
Study: NCT01668316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: 1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work.
Study: NCT00679991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: Applied topically to AVF during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRT-201
Description: Dose escalation study. Drug/placebo administered at the time of fistula creation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: Dose escalation study. Drug/placebo administered at the time of fistula creation
Study: NCT04226716

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment of postural control, body perception and psychosocial factors
Description: Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception and psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events)
Study: NCT02845271

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ389988
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen or paracetamol
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen or paracetamol
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed combination of paracetamol + codeine
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fixed combination of paracetamol + codeine
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed combination of paracetamol + tramadol hydrochloride
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fixed combination of paracetamol + tramadol hydrochloride
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01177072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: 12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Components-Based Intervention
Description: This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
Study: NCT03821571

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
Study: NCT05054296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive general education exercise packet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in supervised and self-directed exercise sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: Wear FitBit for activity tracking

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear FitBit for activity tracking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03670589

Intervention type: RADIATION
Intervention: Radiosurgery gammaknife
Description: This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor

Intervention type: PROCEDURE
Intervention: Microsurgery resection
Description: Classical surgical approach with oto-neurosurgery procedures
Study: NCT04485533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisuXL® Gel
Description: VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day.
Study: NCT03911817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
Study: NCT04485533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisuXL® Gel
Description: VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HYLO®
Description: HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYLO®
Description: HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day
Study: NCT01651741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed and Duolac7S
Description: Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Seaweed and Duolac7S-P
Description: Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
Study: NCT03337776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WhatsApp message
Description: WhatsApp message will be sent to invite subjects to participate in CRC screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone call
Description: Telephone call will be made to invite subjects to participate in CRC screening
Study: NCT03259646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal Education
Description: Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
Study: NCT01174030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: CD07805/47 Gel 0.5% QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: CD07805/47 Gel 0.18% QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel
Description: CD07805/47 Gel 0.18% BID